What we do

CEPI leverages its unique position within the global health and R&D ecosystems to address market failures, building on its track record of bringing together public-sector, private-sector, and academic partners to accelerate the development of vaccines against emerging viral threats.

Medical,Scientists,In,Hazmat,Suit,Working,With,Microscope,And

30+

Number of investors, from governments to philanthropies, who have donated to CEPI

Up to $3.6 bn

Committed investments in R&D&M projects since CEPI's launch

470+

Global R&D&M partners collaborating with CEPI 

Scanning electron micrograph of Lassa virus budding off a cell

Priority pathogens

CEPI supports the development of vaccines, platform technologies and manufacturing innovations to combat priority pathogens for which no licensed vaccines are currently available.

A team of scientists working on vaccine creating in a modern laboratory

Research and development

CEPI is leading a broad range of ambitious programmes that aim to substantially reduce global epidemic and pandemic risk.

A female scientist from Biofarma holding a vile of vaccine in a lab

Process development and manufacturing

CEPI is bolstering global manufacturing capacity in underserved regions and harnessing innovative technologies to improve the speed, scale and access of vaccine manufacturing in response to epidemic and pandemic threats.

Calls for Proposals

Innovators worldwide are invited to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.

Our portfolio

Since our launch in 2017, CEPI has carefully selected and announced over 70 partnerships to advance vaccine candidates against our priority pathogens and platform technologies for use against Disease X.

View our portfolio

Vaccine vials on a conveyor belt in a manufacturing laboratory

Our impact

CEPI has backed the development of 110 vaccine candidates and platform technologies. We have overseen scientific breakthroughs, including the first-ever approved Chikungunya vaccine, and advancing the first-ever Nipah vaccine into Phase I and the first-ever Lassa fever vaccine into Phase II trials. A key player in the COVID-19 response, CEPI also has one of the world’s largest COVID-19 vaccine portfolios and co-led COVAX, which helped to distribute nearly 2 billion doses to 146 nations.

Progress and results